Invaluable Guidance: FDA’s Dean of Drug Reviews on “Enrichment Strategies”
This article was originally published in RPM Report
FDA’s draft guidance on “Enrichment Strategies for Clinical Trials” fulfills an overdue goal from PDUFA IV. It also captures decades of wisdom from the agency’s senior drug review manager.
You may also be interested in...
When it comes to Alzheimer’s Drug development, FDA’s Bob Temple firmly believes regulatory standards are not the problem. “You just need a drug that works.”
CDER’s Robert Temple says FDASIA mostly restates existing FDA authority, but also tells the agency it must better communicate what authority it has and how it will use it.